{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-308821","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.722491+00:00","generated_at":"2026-06-21T01:49:02.081994+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Magenta stops MGTA-117 Cohort 4 dosing after two DLTs; to continue at Cohort 3","bullets":["Three participants dosed in Cohort 4 (0.13 mg/kg); two had dose-limiting toxicities (respiratory SAEs).","First DLT was Grade 4 respiratory SAE; second DLT triggered pre-specified stopping rules.","No DLTs observed in fifteen participants across first three cohorts.","Three of four Cohort 3 participants with paired samples showed cancer blast depletion in blood and bone marrow.","Magenta reported first DLT to FDA; plans to enroll more patients at Cohort 3 (0.08 mg/kg)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-308821","json":"https://secwatch.observer/filing/0001193125-22-308821.json","markdown":"https://secwatch.observer/filing/0001193125-22-308821.md","text":"https://secwatch.observer/filing/0001193125-22-308821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522308821/0001193125-22-308821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522308821/d434259d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T01:49:02.081994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}